Drug-drug interaction study with the cocktail administration of semi-pharmacological dose of multiple drugs to determine the quantitative contribution of OATPs and CYP3A4 to the clearance of the substrate drugs of both OATPs and CYP3A4. - Drug-drug interaction study with the cocktail administration of semi-pharmacological dose of multiple drugs to determine the quantitative contribution of OATPs and CYP3A4 to the clearance of the substrate drugs of both OATPs and CYP3A4.

Subjects who have any hypersensitivity to repaglinide, clarithromycin, bosentan, simeprevir, darunavir, midazolam, rifampicin, itraconazole. b) Subjects who is suffering from acute narrow-angle glaucoma. c) Subjects who is suffering from hypotension( systolic blood pressure < 100mmHg ), hypertension (systolic blood pressure > 140mmHg), diabetes and anemia ( Hb < 12.0g/dL ) at the timing of the screening. d) Subjects who donated or lost over 200 mL (1 unit ) of blood in the past 4weeks or over 400mL (2 units) of blood in the past 3months. e) Subjects who suffer/suffered from severe nervous disease, celebrovascular disease, liver disease, kidney disease, endocrine disease, cardiovascular disease, gastrointestinal disease (including disease which is expected to affect the absorption of test drugs), respiratory disease and metabolic disease. f) Subjects who is confirmed to have severe clinical abnormalities judged by the diagnostics or physical examination by chief doctor or associate doctors. g) Subjects who is suffering from clinically severe diseases within 30 days before the administration of test drugs. h) Subjects who take medicine, health foods including St. John's wort, foods or drinks containing greapefruit, orange, and apple, and supplements, and cannot stop taking these during this clinical study. i) Subjects who smoke or take nicotine within 30 days before the administration of test drugs, and cannot stop smoking during this clinical study j) Subjects who take foods/drinks containing alcohol or caffeine one day before the date of hospital admission, and cannot stop taking these until the final day of this study. k) Subjects whose results of alcohol breath test or uninary drug screening are positive at the timing of screening. l) Subjects whose results of any tests of serological reaction for HBs antigen, HCV antibody or HIV antigen and antibody are positive m) Subjects who is not suitable for this study judged by chief doctor or associte doctors.